Assessing Long-term Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions-LEA
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms LEA
- Sponsors AbbVie
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.
- 28 Nov 2017 Planned number of patients changed from 500 to 200.
- 28 Nov 2017 Planned initiation date changed from 30 Sep 2017 to 30 Dec 2017.